A
Aligos Therapeutics, Inc. (ALGS)
NCM – Real Time Price. Currency in USD
6.66
-0.38 (-5.40%)
At close: Mar 27, 2026, 4:00 PM EDT
6.57
-0.09 (-1.35%)
After-hours: Mar 27, 2026, 7:50 PM EDT
Get all premium features to the best stock analysis tool
NCM – Real Time Price. Currency in USD
6.66
-0.38 (-5.40%)
At close: Mar 27, 2026, 4:00 PM EDT
6.57
-0.09 (-1.35%)
After-hours: Mar 27, 2026, 7:50 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 3.90 | 6.05 | 10 | |
| Quick ratio | 3.90 | 5.63 | 10 | |
| Debt to Equity | 0.10 | 0.30 | 9.0 | |
| Debt to Assets | 0.06 | 1.04 | 9.0 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 7.8 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 14M | 16M | 4M | 2M | 2M |
| Gross Profit | 10M | 12M | 1M | 1M | 1M |
| Operating Income | -98M | -87M | -89M | -88M | -88M |
| Net Income | -96M | -88M | -131M | -24M | -24M |
| EBITDA | -94M | -84M | -87M | -87M | -87M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 7.18 | -5.37 | 3.0 |
| Next quarter | -65.46 | -13.25 | 1.0 |
| Current year | -22.23 | -163.89 | 1.0 |
| Next year | 4.71 | 23.59 | 7.0 |
| Weighted average score | 3.0 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | -77.18 | 36.96 | 37.17 | 11.01 | 7.0 |
| Y/Y | -73.12 | 75.8 | 85.4 | -18.47 | 5.5 |
| 3y average | -35.83 | 13.54 | 55.42 | -1.07 | 5.0 |
| 5y average | 222.11 | 9.51 | 53.35 | -4.96 | 6.8 |
| Weighted average score | 6.1 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $18.4M significantly exceed its total debt $5.2M, ensuring strong financial flexibility
Total current assets $82.9M exceed Total current liabilities $21.2M, highlighting excellent liquidity
Debt-to-equity ratio (0.1) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$21.8M limits the company's ability to reinvest or pay down debt